University of Tennessee Graduate School of Medicine
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Tennessee Graduate School of Medicine sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
University of Tennessee Graduate School of Medicine: 20 sponsored US clinical trials, 9 recruiting.
University of Tennessee Graduate School of Medicine sponsors 20 registered US clinical trials on ClinicalTrials.gov, 9 of them currently recruiting, and 9 completed. 6 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Fetal Growth Complications, with 1 trials.
Top-decile sponsor footprint
University of Tennessee Graduate School of Medicine ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
20 total, page 1 of 1
REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennessee Medical Center
NCT07223437
Cardiometabolic Disease and Substrate Metabolism
NCT07565727
Planning Together: A Couple-based, Multi-level Prenatal Contraceptive Education Program for Economically Marginalized Families
NCT07214012
Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure
NCT07205068
Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy
NCT07153614
Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia
NCT06802861
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
NCT07133880
Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study
NCT06800105
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
NCT04655170
Personalized Post-Operative Pain Management
NCT06669650
Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair
NCT06953635
Assessing Whole-body Metabolism in Gynecologic Cancers in Response to a Single Chemotherapy Cycle and/ or Immunotherapy
NCT07393633
Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load
NCT05968846
Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy
NCT06039319
A Novel Therapeutic Approach to Treat Chronic Pelvic Pain
NCT05467241
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
NCT03678259
Comparison of Intravenous V/S Nasal Atomizer Delivery of Midazolam for Conscious Sedation for No-scalpel Vasectomy
NCT06449365
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers
NCT02291016
Dexmedetomidine Versus Propofol for Prolonged Sedation in Critically Ill Trauma and Surgical Patients
NCT02548923
Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients
NCT02612948
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 4 | 6 |
Where University of Tennessee Graduate School of Medicine enrollment is open (later-stage tilt)
9 recruiting of 20 indexed (45% open); 9 completed (45%).
Phase mix: 6 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: Fetal Growth Complications (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Tennessee Graduate School of Medicine: open-pipeline peers nationwide
Peers matched on 20 registered trials and 45% open enrollment, not the therapeutic-area sidebar.
University of Tennessee Graduate School of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 45% open enrollment (± trial volume)
- Retina Foundation of the Southwest · 45% recruiting · 11 trials
- Southern College of Optometry · 45% recruiting · 11 trials
- 4D Molecular Therapeutics · 44% recruiting · 9 trials
- American Heart Association · 44% recruiting · 9 trials
Related
What to do with this University of Tennessee Graduate School of Medicine page
20 registered trials is a research-attention snapshot, not an endorsement of University of Tennessee Graduate School of Medicine or any single study.
- 9 of University of Tennessee Graduate School of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Fetal Growth Complications is the condition University of Tennessee Graduate School of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Fetal Growth Complications trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Tennessee Graduate School of Medicine pipeline card: 20 registered trials from official public datasets.Report a data error.